Surrozen Inc
SRZN
NASDAQ
Biotechnology
$23.96
USD
+0.23 (+0.97%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $278.91M
Volume 212.9K
Revenue
$11.51M
TTM
-8.8%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-332.13M
TTM
-1889.2%
YoY
Operating Cash Flow
$-34.76M
TTM
-86.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 1.0 | 1.0 | 0.5 | 5.0 | 5.0 |
YoY Growth | — | -90.2% | -19.4% | +408.6% | +408.6% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 1.0 | 1.0 | 0.5 | 5.0 | 5.0 |
Selling, General & Administrative | 4.0 | 4.1 | 4.2 | 6.1 | 6.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 10.0 | 11.9 | 13.2 | 15.5 | 15.4 |
Operating Income | -9.0 | -10.9 | -12.6 | -10.5 | -10.4 |
EBITDA | -8.9 | -10.8 | -12.6 | -10.4 | -10.3 |
Other Income / Expense | 47.7 | -61.7 | -171.3 | -118.0 | 59.6 |
Total Other Income / Expense | 48.8 | -60.8 | -170.5 | -117.0 | 60.5 |
Income Before Income Taxes | 39.7 | -71.6 | -183.2 | -127.5 | 50.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | 39.7 | -71.6 | -183.2 | -127.5 | 50.2 |
Consolidated Net Income / Loss | 39.7 | -71.6 | -183.2 | -127.5 | 50.2 |
Net Income Attributable to Common Shareholders | 21.8 | -71.6 | -183.2 | -127.5 | 32.0 |
Basic EPS | $2.55 | -$8.36 | -$19.97 | -$11.65 | $2.75 |
Diluted EPS | $2.55 | -$8.36 | -$19.97 | -$11.65 | -$0.41 |
Basic Shares Outstanding | 8.5M | 8.6M | 9.2M | 10.9M | 11.7M |
Diluted Shares Outstanding | 8.5M | 8.6M | 9.2M | 10.9M | 23.1M |